2015 Annual Meeting: Immunology On Demand

You can earn up to 9.25 AMA PRA Category 1 Credit(s). This activity has also been designated by the ABAI for 3.5 MOC Part II Self-Assessment credits. Cost: $185 $95 for College Members, $279 $139 for non-members.

This package of courses includes the following immunology related sessions from the 2015 ACAAI Annual Meeting in San Antonio:

  • Human Microbiome: The Interface of Immunology and Microbiology
  • Managing Non-Infectious Complications of Common Variable Immunodeficiency
  • Altering the Natural History of Allergic Diseases With Immunotherapy
  • W20 Are You Ready for SCID Newborn Screening?
  • W29 Immunotherapy in 2015: The Nuts and Bolts of SCIT and SLIT


Release Date: 12/15/2015
Expiration Date: 12/14/2018


The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 9.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity is not supported by commercial interests. 

Learning Objectives

• Discuss facets of modulation of gut microbiota that lead to disruption of host-microorganism homeostasis and contributes to the development of non-communicable inflammatory diseases
• Explain how gut microbiota dysbiosis contributes to aberrant immune development and the development of allergic disease and asthma
• Discuss the implications of gut microbiota modification for treatment and prevention of allergic disease and asthma

• Recognize and treat the pulmonary complications of common variable immunodeficiency
• Recognize and treat the autoimmune complications of common variable immunodeficiency
• Describe malignancies associated with common variable immunodeficiency diseases

• Recognize the similarities and differences in logistics, efficacy, and safety of SLIT and SCIT for inhalant allergies
• Discuss results of recent food allergy immunotherapy clinical trials
• Discuss likely future strategies for performing immunotherapy, including using adjuvants, biologicals, and peptides

• Recognize the important steps for implementing statewide SCID newborn screening; and discuss the basis of TREC screening, including the conditions identified by this test, and the proper next steps to be taken after an abnormal newborn screening test

• Explain the differences between standardized and nonstandardized extracts
• Compose a therapeutic mix for immunotherapy through review of the literature
• Write prescriptions for immunotherapy which contain safe and effective doses of each component according to current guidelines and best clinical practice for the benefit of patient care
• Use current guidelines to improve the safety and effectiveness of immunotherapy in the office
• Explore the literature regarding SLIT
• Explore adherence to IT

Additional information

Todd A. Mahr, MD, FACAAI -- Speaker: Aerocrine, Genentech, GlaxoSmithKline, Meda, Merck, Mylan, Sanofi, Teva

Anthony Montanaro, MD, FACAAI -- Supported/Contracted Reearch: Circassia, Genentech, GlaxoSmithKline, Merck, Teva

Chitra Dinakar, MD, FACAAI -- Consultant/Advisor: Aerocrine; Supported/Contracted Research: GlaxoSmithKline, Merck, Teva

Myron J. Zitt, MD, FACAAI -- Consultant/Advisor: Integrity, Sanofi, McNeil, Boehringer Ingelheim; Speaker: Integrity, Mylan, Meda, Boston Scientific

Harold S. Nelson, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Circassia, Merck, Pearl Therapeutics; Supported/Contracted Research: Circassia

Stanley M. Fineman, MD, MBA, FACAAI -- Speaker: AstraZeneca, Genentech, Meda, Merck, Mylan; Supported/Contracted Research: Genentech, Meda

Lisa K. Kobrynski, MD, MPH, FACAAI -- Supported/Contracted Research: Baxter; Speaker: Baxter, CSL Behring

John J. Oppenheimer, MD, FACAAI -- Consultant/Advisor: GlaxoSmithKline, Meda, Mylan; Supported/Contracted Research: AstraZeneca, MedImmune, Novartis


The following have no financial relationships to disclose:

Michael B. Foggs, MD, FACAAI

Fernando D. Martinez, MD

Lanny J. Rosenwasser, MD, FACAAI

Yvonne Huang, MD

Gerald B. Lee, MD

John M. Routes, MD, FACAAI

William T. Shearer, MD, PhD

Kari C. Nadeau, MD, PhD

Bryan L. Martin, DO, FACAAI

Course summary
Available credit: 
  • 9.25 AMA PRA Category 1 Credit™
  • 9.25 Attendance
  • 3.50 MOC
Course opens: 
Course expires: 

Available Credit

  • 9.25 AMA PRA Category 1 Credit™
  • 9.25 Attendance
  • 3.50 MOC


Please login or create an account to take this course.